Sofosbuvir inhibits yellow fever virus in vitro and in patients with acute liver failure.

Introduction And Objectives: Direct antiviral agents (DAAs) are very efficient in inhibiting hepatitis C virus and might be used to treat infections caused by other flaviviruses whose worldwide detection has recently increased. The aim of this study was to verify the efficacy of DAAs in inhibiting yellow fever virus (YFV) by using drug repositioning (a methodology applied in the pharmaceutical industry to identify new uses for approved drugs).

Materials And Methods: Three DAAs were evaluated: daclatasvir, sofosbuvir and ledipasvir or their combinations.